DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
DBV Technologies (DBVT) will report third-quarter 2026 financial results and provide a business update on October 28, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DBV Technologies (DBVT) will report third-quarter 2026 financial results and provide a business update on October 28, 2026.
The company will host an investor conference call and live audio webcast at 5:00 p.m. ET that day to review the results. The webcast will be available through the Events section of the company’s website.
Key Terms
epicutaneous immunotherapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Châtillon, France, October 27, 2026
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
- Company to host investor conference call and webcast at 5:00pm ET
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Wednesday, October 28th, at 5:00 p.m. ET to review its third quarter 2026 financial results and provide a business update.
Interested participants may access this call via the teleconferencing numbers below and asking to join the DBV Technologies Third Quarter 2026 Results call:
United States: +1-877-344-8082
International: +1-213-992-4618
A live webcast of the call will be available on the Events section of the Company's website here.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN® Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Virginie Boucinha
DBV Technologies
virginie.boucinha@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
